2019. The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. Farmeconomia. Health economics and therapeutic pathways. 20, 1 (Jul. 2019). DOI:https://doi.org/10.7175/fe.v20i1.1435.